Trials / Completed
CompletedNCT05116891
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
A Phase 1 / 2 Study of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Cantargia AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAN04 (nadunolimab) | FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP |
| DRUG | mFOLFOX | mFOLFOX/CAN04 |
| DRUG | DTX | DTX/CAN04 |
| DRUG | G/C | G/C/CAN04 |
Timeline
- Start date
- 2021-09-22
- Primary completion
- 2023-06-23
- Completion
- 2023-06-23
- First posted
- 2021-11-11
- Last updated
- 2023-07-03
Locations
6 sites across 2 countries: France, Spain
Source: ClinicalTrials.gov record NCT05116891. Inclusion in this directory is not an endorsement.